Drugs / Polyribosil-Ribitol-Phosphate (PRP) vaccine
last change Mar 2006 re-read 2 minutes ago

Polyribosil-Ribitol-Phosphate (PRP) vaccine

Vaccine

Developed for
haemophilus infectious disease
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00169442 Feb 2005 → Mar 2006 diphtheria, haemophilus infectious disease, hepatitis B virus infection, tetanus GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Polyribosil-Ribitol-Phosphate (PRP) vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00169442
Modality Vaccine “polysaccharide vaccineNCT00169442
Route Intramuscular “administered intramuscularly into the right upper thigh” NCT00169442